CareTrust REIT, Inc
CTRE
$36.26
+2.28%
CareTrust REIT, Inc. is a self-administered, publicly traded real estate investment trust that owns, acquires, finances, develops, and leases skilled nursing facilities, seniors housing, and other healthcare-related properties, generating revenue primarily through triple-net leases in which tenants bear property-level operating costs. With a market capitalization of roughly $7.4-8.8 billion and only 43 employees, CareTrust is a highly efficient, externally growth-oriented net-lease landlord that has carved out a distinct identity as one of the few pure-play consolidators of skilled nursing and seniors housing real estate in the U.S., competing against larger diversified healthcare REITs and private capital. The current investor narrative centers on an aggressive acquisition-driven expansion that has roughly doubled quarterly revenue year-over-year (Q1 2026 revenue of $142.8 million versus $71.6 million a year earlier), funded heavily through equity issuance, alongside a debate over whether the trust's premium valuation and sub-4% dividend yield adequately compensate for tenant concentration and operator credit risk in the skilled nursing space. Sentiment has cooled recently, with the stock down double digits over three months despite a strong-buy consensus, as investors digest dilution from capital raises and the sustainability of external growth in a higher-rate environment.…
CTRE
CareTrust REIT, Inc
$36.26
Investment Opinion: Should I buy CTRE Today?
The synthesized recommendation is a Hold with a positive bias, reflecting the strong fundamental growth and analyst consensus but tempered by near-term technical weakness and valuation concerns. The core thesis is that CareTrust's aggressive acquisition strategy has delivered exceptional revenue growth (99.29% YoY in Q1 2026) and robust margins (EBITDA margin of 85.76%), but the stock's premium valuation (EV/EBITDA of 17.44x) and dilution from equity issuance (shares up 19.2% YoY) limit immediate upside. The analyst consensus is strong buy with an average target of $43.64, implying 19.2% upside, but the stock's 15.33% three-month decline suggests the market is skeptical about the sustainability of this growth. Supporting evidence includes: 1) revenue growth of 99.29% YoY, 2) net margin of 56.18% and operating margin of 65.14%, 3) free cash flow of $397.14 million covering dividends, and 4) a low debt-to-equity of 0.22. However, the PEG ratio of 0.245 is attractive, but for REITs, this metric can be distorted by acquisition-driven earnings. The biggest risks are further dilution from equity raises, margin compression from higher financing costs, and a potential slowdown in acquisition volume. The rating would upgrade to Buy if the stock stabilizes above $40 and the company demonstrates accretive growth without significant dilution, or downgrade to Sell if revenue growth decelerates below 20% or if a major tenant default occurs. Relative to its history, the PE of 23.03x is in the middle-to-upper portion of its range (18.08x to 25.45x), and P/B of 1.82x is near the low end, suggesting the stock is fairly valued to slightly overvalued on earnings but reasonably valued on assets.
Sign up to view all
CTRE 12-Month Price Forecast
The forward-looking view is neutral with a balanced risk/reward. On the positive side, CareTrust's acquisition engine has delivered exceptional revenue growth and robust margins, and the balance sheet remains conservatively leveraged. However, the stock's premium valuation, dilution from equity issuance, and recent technical weakness suggest that much of the good news is priced in. The analyst consensus is strongly positive, but the market's skepticism is evident in the 18.18 percentage point underperformance versus SPY over three months. I would upgrade to bullish if the company demonstrates accretive growth without further dilution and the stock reclaims $40, or downgrade to bearish if revenue growth decelerates below 20% or if a major tenant default occurs.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on CareTrust REIT, Inc's 12-month outlook, with a consensus price target around $43.64 and implied upside of +20.4% versus the current price.
Average Target
$43.64
0 analysts
Implied Upside
+20.4%
vs. current price
Analyst Count
—
covering this stock
Price Range
$41 - $49
Analyst target range
Coverage is solid with 14 analysts, and the consensus is decisively bullish: a recommendation of "strong_buy" with a mean rating of 1.43 (where 1.0 is a strong buy) and an average target price of $43.64. Against the current price of $36.62, that implies roughly 19.2% upside to the consensus target, a wide gap that suggests the sell-off has outpaced fundamental deterioration and that the Street views the recent weakness as an opportunity rather than a warning.
The target range of $41.00 to $49.00 is moderately wide — about 19.5% between low and high — signaling meaningful dispersion in assumptions. The high target of $49.00 (roughly 33.8% above the current price) likely assumes continued accretive acquisitions, multiple expansion toward the upper end of the historical PE band, and successful deployment of recent equity raises, while the low target of $41.00 (about 12.0% upside) still implies a positive outcome but prices in slower deal flow or margin compression from higher financing costs. Institutional ratings show a stable-to-improving pattern — BMO Capital upgraded to Outperform from Market Perform in January 2026, and Wells Fargo, UBS, RBC, Jefferies, and KeyBanc have maintained Buy/Overweight/Outperform stances through mid-2026 — with only Cantor Fitzgerald sitting at Neutral, reinforcing that the bear case is a minority view and that conviction among covering analysts remains strong despite the stock's three-month slide.
Bulls vs Bears: CTRE Investment Factors
The bull case rests on explosive revenue growth (99.29% YoY in Q1 2026), a fortress balance sheet with debt-to-equity of 0.22, and a strong buy consensus with 19.2% upside to the average target. However, the bear case highlights premium valuation (EV/EBITDA of 17.44x), significant dilution from equity issuance (shares up 19.2% YoY), margin compression, and a sharp technical downtrend (-15.33% over three months). Currently, the bear evidence appears stronger in the near term given the stock's relative underperformance and margin trends, but the bull case has substantial fundamental support from growth and analyst sentiment. The single most important tension is whether the acquisition engine can continue to deliver accretive growth without further diluting shareholders or straining the balance sheet—if deal flow slows or financing costs rise, the premium multiple could compress sharply.
Bullish
- Explosive revenue growth from acquisitions: Q1 2026 revenue of $142.78 million grew 99.29% year-over-year from $71.65 million, extending a multi-quarter acceleration from $86.03 million in Q2 2025 to $135.05 million in Q4 2025. This trajectory reflects an aggressive acquisition engine that has roughly doubled the top line in a year.
- Strong analyst consensus and upside: 14 analysts rate the stock a strong buy with a mean rating of 1.43 and an average target price of $43.64, implying 19.2% upside from the current $36.62. The low target of $41.00 still represents 12.0% upside, indicating broad-based positive sentiment.
- Fortress balance sheet with low leverage: Debt-to-equity of just 0.22 and a current ratio of 1.54 provide substantial cushion, while $223.21 million in cash supports near-term liquidity. Trailing free cash flow of $397.14 million comfortably covers the $74.81 million in quarterly dividends.
- High margins and capital-light model: Q1 2026 EBITDA margin was 85.76% and operating margin 65.14%, reflecting the triple-net lease structure where tenants bear property-level costs. Capital expenditures of only $3.16 million in Q1 2026 highlight the capital-light nature of the business.
Bearish
- Premium valuation versus peers: Price-to-sales of 15.45x and EV/EBITDA of 17.44x sit at a premium to typical net-lease healthcare REIT multiples in the low-to-mid teens. The dividend yield of 3.52% is below the 4-5% range common among skilled nursing REITs, meaning investors are accepting lower current income for growth.
- Dilution from aggressive equity issuance: Q1 2026 alone saw $127.9 million of common stock issued, and shares outstanding have risen from 187.15 million in Q1 2025 to 223.01 million in Q1 2026, a 19.2% increase. This dilutes per-share metrics even as absolute revenue compounds, and the payout ratio of 80.9% leaves limited retained-cash buffer.
- Margin compression and rising interest expense: Net margin compressed from 82.41% in Q4 2025 to 56.18% in Q1 2026, and gross margin fell to 56.85% from 58.93% in Q4 2025 and 96-97% in earlier 2025 quarters. Interest expense jumped to $11.24 million from $6.67 million a year earlier, underscoring increasing reliance on debt financing.
- Technical downtrend and relative underperformance: The stock is down 15.33% over three months and trails SPY by 18.18 percentage points over the same period. At $36.62, it sits 16.0% below its 52-week high of $43.62 and only 7.9% above its 52-week low of $33.72, signaling deteriorating momentum.
CTRE Technical Analysis
CTRE is in a medium-term downtrend within a broader range-bound structure, having fallen 15.33% over the past three months while posting a modest 4.84% gain over the trailing year. At $36.62, the stock sits at roughly 29.4% of its 52-week range of $33.72 to $43.62 — closer to the lower end than the top — which signals deteriorating momentum rather than a value floor, especially given the stock is 16.0% below its 52-week high. The 1-year gain of 4.84% masks significant internal volatility, with a max drawdown of -17.86% indicating the recovery has been uneven and the trend fragile.
Short-term momentum is clearly negative and diverging from the longer-term picture: the 1-month change of -1.48% and 3-month change of -15.33% show accelerating weakness, while the 6-month change of -3.53% and YTD gain of 0.85% reveal that essentially all of 2026's gains have been erased since mid-year. This divergence — a positive 1-year return colliding with a sharply negative 3-month trend — typically signals either a mean-reversion bounce candidate or the early stage of a trend reversal, and the failure to hold the July highs near $43.40 argues for caution. Relative strength confirms the underperformance: CTRE trails SPY by 18.18 percentage points over three months and 8.29 points over one year, even as the broader market gained 13.13% over the same 12-month window.
Key technical levels are well defined: support rests at the 52-week low of $33.72, roughly 7.9% below the current price, while resistance sits at the 52-week high of $43.62, about 19.1% above. A breakdown below $33.72 would confirm the downtrend and likely trigger momentum selling, whereas a reclaim of the $40-43 zone would signal trend repair. The beta of 0.774 indicates the stock is roughly 23% less volatile than the market, which softens position-sizing risk but also means CTRE will likely lag in strong risk-on rallies; the short ratio of 5.01 (about five days of average volume to cover shorts) suggests moderate bearish positioning that could fuel a squeeze on any positive catalyst, with average volume around 2.45 million shares providing adequate liquidity.
Beta
0.77
0.77x market volatility
Max Drawdown
-18.3%
Largest decline past year
52-Week Range
$34-$44
Price range past year
Annual Return
+6.7%
Cumulative gain past year
| Period | CTRE Return | S&P 500 |
|---|---|---|
| 1m | -2.5% | +0.7% |
| 3m | -13.5% | +3.0% |
| 6m | -7.5% | +6.8% |
| 1y | +6.7% | +11.9% |
| ytd | -0.1% | +12.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CTRE Fundamental Analysis
Revenue is growing at an extraordinary pace: Q1 2026 revenue of $142.78 million represents 99.29% year-over-year growth versus $71.65 million in Q1 2025, extending a clear multi-quarter acceleration from $86.03 million in Q2 2025, $104.27 million in Q3 2025, and $135.05 million in Q4 2025. This trajectory reflects an aggressive acquisition engine rather than organic rent escalation, and the sequential cadence — roughly $18-31 million added per quarter — implies the trust is deploying capital at a rapid clip. The investment case therefore hinges on deal flow sustainability and the spread between acquisition cap rates and the cost of capital, since growth is externally manufactured and dependent on continued access to equity and debt markets.
Profitability is robust for a REIT: Q1 2026 net income was $80.21 million with a net margin of 56.18%, operating margin of 65.14%, and EBITDA of $122.45 million (an EBITDA margin of 85.76%). Gross margin of 56.85% in Q1 2026 is down from 58.93% in Q4 2025 and well below the 96-97% gross margins reported in earlier 2025 quarters, a shift that likely reflects the consolidation of newly acquired properties with different lease economics and higher property-level costs. Net margin has compressed from 82.41% in Q4 2025 to 56.18% in Q1 2026, partly due to a jump in interest expense to $11.24 million from $6.67 million a year earlier, underscoring that the growth is increasingly financed with debt.
Balance sheet health remains a relative strength: debt-to-equity of just 0.22 and a current ratio of 1.54 provide substantial cushion, while trailing free cash flow of $397.14 million comfortably covers the $74.81 million in quarterly dividends paid. Operating cash flow of $90.37 million in Q1 2026 versus capital expenditure of only $3.16 million highlights the capital-light, triple-net model, and the $223.21 million cash balance supports near-term liquidity. However, ROE of 7.94% and ROA of 4.44% are modest, and the payout ratio of 80.9% leaves limited retained-cash buffer, meaning future growth will likely require continued equity issuance — Q1 2026 alone saw $127.9 million of common stock issued — which dilutes per-share metrics even as absolute revenue compounds.
Quarterly Revenue
$142783000.0B
2026-03
Revenue YoY Growth
+99.3%
YoY Comparison
Gross Margin
56.9%
Latest Quarter
Free Cash Flow
$397136000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CTRE Overvalued?
Because CareTrust is profitable (Q1 2026 net income of $80.21 million), the PE ratio is the appropriate primary metric, and the trailing PE of 23.03x versus a forward PE of 19.50x implies the market expects meaningful earnings growth — roughly 18% — over the next twelve months, consistent with the acquisition pipeline and analyst EPS estimates of $1.90. The PEG ratio of 0.245 is strikingly low, suggesting the stock is inexpensive relative to its growth rate, though for REITs this metric should be treated cautiously given the distortion from acquisition-driven earnings and depreciation conventions.
On a peer basis, the picture is more nuanced: the price-to-book ratio of 1.82x is reasonable for a healthcare REIT, but the price-to-sales ratio of 15.45x and EV/EBITDA of 17.44x sit at a premium to typical net-lease healthcare REIT multiples in the low-to-mid teens, reflecting the market's willingness to pay up for CareTrust's growth and clean balance sheet. The dividend yield of 3.52% is below the 4-5% range common among skilled nursing REITs, meaning investors are accepting a lower current income in exchange for growth — a premium that is justified only if the acquisition engine keeps delivering. The EV/Sales of 17.21x is elevated and warrants scrutiny, as it capitalizes revenue that is partly non-organic.
Historically, CTRE's PE has ranged widely — from 18.08x in Q4 2025 to 25.45x in Q1 2026 and over 36x in Q3 2024 — placing the current 23.03x in the middle-to-upper portion of its own band, while the price-to-book of 1.82x is near the low end of its historical 1.69x-2.42x range. This combination suggests the market is pricing in optimistic earnings expectations while the asset base is valued conservatively, a mixed signal that argues for patience until either earnings delivery validates the multiple or the price adjusts toward the lower end of its historical valuation range.
PE
23.0x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 18x~42x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
17.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are centered on the sustainability of acquisition-driven growth and its funding. Revenue doubled year-over-year to $142.78 million in Q1 2026, but this was accompanied by a 19.2% increase in shares outstanding (from 187.15 million to 223.01 million) and a jump in interest expense to $11.24 million from $6.67 million. The payout ratio of 80.9% leaves little retained cash, meaning future growth will likely require continued equity or debt issuance, which could further dilute per-share metrics. Additionally, net margin compressed from 82.41% in Q4 2025 to 56.18% in Q1 2026, and gross margin fell to 56.85% from 96-97% in earlier 2025 quarters, reflecting the consolidation of newly acquired properties with different lease economics. Tenant concentration in skilled nursing facilities exposes the company to operator credit risk, as tenant distress could impair rental income. Market and competitive risks include valuation compression if the stock's premium multiples (EV/EBITDA of 17.44x, P/S of 15.45x) revert toward peer levels in the low-to-mid teens. The beta of 0.774 indicates lower volatility than the market, but the stock has underperformed SPY by 18.18 percentage points over three months, and a continued rise in interest rates could increase financing costs and make the dividend yield of 3.52% less attractive relative to bonds. Competition for acquisitions from larger healthcare REITs and private capital could drive cap rates lower, compressing investment spreads. The worst-case scenario involves a combination of slowing acquisition volume, a major tenant default, and a spike in financing costs, which could trigger a sharp re-rating. From the current price of $36.62, a decline to the 52-week low of $33.72 would represent a 7.9% loss, while a drop to the analyst low target of $41.00 is not applicable as it is above the current price; however, if the stock breaks below $33.72, the next support could be significantly lower, potentially testing the max drawdown of -17.86% from the 52-week high, implying a price near $30.00, or a 18% loss from current levels.
FAQ
The key risks include: 1) Dilution risk: shares outstanding increased 19.2% YoY to 223.01 million, and further equity issuance to fund acquisitions could dilute per-share metrics. 2) Margin compression: net margin fell from 82.41% in Q4 2025 to 56.18% in Q1 2026, and interest expense jumped to $11.24 million from $6.67 million, which could continue to pressure profitability. 3) Tenant concentration and credit risk: as a pure-play skilled nursing REIT, a major tenant default could impair rental income. 4) Valuation compression: EV/EBITDA of 17.44x is at a premium to peers, and a re-rating to peer multiples could lead to a 20-30% decline. 5) Technical downtrend: the stock is down 15.33% over three months and could break below the 52-week low of $33.72, triggering further selling.
Our 12-month forecast has three scenarios: Bull case (25% probability) targets $43.64-$49.00, assuming continued accretive acquisitions and multiple expansion. Base case (55% probability) targets $38.00-$43.64, assuming moderate acquisition activity and stable margins. Bear case (20% probability) targets $33.72-$38.00, assuming a slowdown in acquisitions and margin compression. The most likely scenario is the base case, with a target range around the analyst average of $43.64, implying 19.2% upside. The key assumption is that revenue growth decelerates to 20-30% YoY but remains healthy, and the company avoids major tenant issues.
CTRE's valuation is mixed. On a trailing PE basis, 23.03x is in the middle-to-upper portion of its historical range (18.08x to 25.45x), suggesting fair valuation relative to its own history. However, EV/EBITDA of 17.44x and P/S of 15.45x are at a premium to typical net-lease healthcare REIT multiples in the low-to-mid teens, indicating the market is paying up for growth. The PEG ratio of 0.245 is attractive, but for REITs, this metric can be distorted by acquisition-driven earnings. The dividend yield of 3.52% is below the 4-5% range common among peers, meaning investors are accepting lower current income for growth. Overall, the stock appears fairly valued to slightly overvalued on earnings but reasonably valued on assets (P/B of 1.82x near the low end of its historical range).
CTRE presents a mixed risk/reward proposition. On the positive side, the stock trades at $36.62, implying 19.2% upside to the analyst average target of $43.64, and the company has delivered explosive revenue growth of 99.29% YoY in Q1 2026. However, the stock is down 15.33% over three months and sits just 7.9% above its 52-week low of $33.72, reflecting near-term bearish momentum. The biggest downside risk is further dilution from equity issuance (shares up 19.2% YoY) and potential margin compression from rising interest expense. For long-term investors with a tolerance for volatility and a belief in the acquisition-driven growth story, CTRE could be a good buy on weakness, but near-term traders may want to wait for a technical stabilization above $40.
CTRE is more suitable for long-term investment given its growth-oriented acquisition strategy, low beta of 0.774, and stable dividend (yield 3.52%). The company's earnings visibility is moderate, supported by triple-net leases, but the acquisition-driven growth model introduces variability. Short-term trading is less attractive due to the current downtrend and relative underperformance (-18.18 percentage points vs. SPY over three months). A suggested minimum holding period is 2-3 years to allow the acquisition pipeline to mature and for margin trends to stabilize. Investors should monitor quarterly earnings for signs of sustainable growth and balance sheet discipline.